Diplomat Pharmacy Inc (NYSE:DPLO) Receives $10.00 Consensus Price Target from Brokerages

Diplomat Pharmacy Inc (NYSE:DPLO) has received a consensus rating of “Hold” from the seventeen ratings firms that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $10.00.

Several analysts have issued reports on the company. Barclays set a $7.00 target price on Diplomat Pharmacy and gave the stock a “buy” rating in a research note on Friday, August 9th. Wells Fargo & Co upped their target price on Diplomat Pharmacy from $5.00 to $5.50 and gave the stock a “market perform” rating in a research note on Tuesday, August 13th. Zacks Investment Research lowered Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Wednesday, August 14th. ValuEngine raised Diplomat Pharmacy from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Finally, Deutsche Bank assumed coverage on Diplomat Pharmacy in a research note on Thursday, September 12th. They issued a “sell” rating and a $4.00 target price for the company.

Hedge funds have recently made changes to their positions in the business. Royal Bank of Canada lifted its position in Diplomat Pharmacy by 184.8% in the second quarter. Royal Bank of Canada now owns 4,782 shares of the company’s stock valued at $29,000 after purchasing an additional 3,103 shares during the last quarter. KBC Group NV bought a new stake in Diplomat Pharmacy in the second quarter valued at approximately $46,000. Bank of Montreal Can lifted its position in Diplomat Pharmacy by 138.4% in the second quarter. Bank of Montreal Can now owns 11,444 shares of the company’s stock valued at $70,000 after purchasing an additional 6,644 shares during the last quarter. BNP Paribas Arbitrage SA lifted its position in Diplomat Pharmacy by 446.9% in the first quarter. BNP Paribas Arbitrage SA now owns 13,104 shares of the company’s stock valued at $76,000 after purchasing an additional 10,708 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. bought a new stake in Diplomat Pharmacy in the second quarter valued at approximately $77,000. Hedge funds and other institutional investors own 84.58% of the company’s stock.

DPLO traded up $0.13 during midday trading on Friday, hitting $5.31. The stock had a trading volume of 43,711 shares, compared to its average volume of 796,629. The company has a market cap of $395.07 million, a P/E ratio of 26.70 and a beta of 1.00. The business has a fifty day moving average of $5.65 and a 200 day moving average of $5.52. The company has a debt-to-equity ratio of 1.53, a quick ratio of 0.66 and a current ratio of 0.99. Diplomat Pharmacy has a 1 year low of $4.17 and a 1 year high of $21.48.

Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Friday, August 9th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.01). The firm had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.23 billion. Diplomat Pharmacy had a negative return on equity of 4.01% and a negative net margin of 8.93%. The firm’s quarterly revenue was down 9.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.05) EPS. On average, equities research analysts anticipate that Diplomat Pharmacy will post -0.81 earnings per share for the current year.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Recommended Story: Are all No-Load Funds Equal?

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.